ImmunityBio, Inc. Common Stock
IBRX Real Time Price USDRecent trades of IBRX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Mar. 06, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IBRX's directors and management
Government lobbying spending instances
-
$45,000 Oct 08, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Jul 19, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$60,000 Apr 09, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$60,000 Jan 17, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of treating age-related and inflammatory diseases Oct. 15, 2024
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Oct. 08, 2024
-
Patent Title: Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags Sep. 10, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Aug. 20, 2024
-
Patent Title: Advanced avatar dendritic cells Jul. 23, 2024
-
Patent Title: Nant covid vaccine cross reactivity Jun. 25, 2024
-
Patent Title: Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment May. 28, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods May. 07, 2024
-
Patent Title: Generating cik nkt cells from cord blood Mar. 19, 2024
-
Patent Title: Method of inducing immunity against sars-cov-2 using spike (s) and nucleocapsid (n)-etsd immunogens delivered by a replication-defective adenovirus Jan. 02, 2024
-
Patent Title: Modified nk-92 hank003 cells for the clinic Sep. 12, 2023
-
Patent Title: Fc-epsilon car May. 09, 2023
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Jan. 10, 2023
-
Patent Title: Mononuclear cell derived nk cells Sep. 27, 2022
-
Patent Title: Generating cik nkt cells from cord blood Jun. 07, 2022
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Apr. 19, 2022
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors Jan. 25, 2022
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Jan. 04, 2022
-
Patent Title: Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer Dec. 28, 2021
-
Patent Title: Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Sep. 28, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of IBRX in WallStreetBets Daily Discussion
Recent insights relating to IBRX
Recent picks made for IBRX stock on CNBC
ETFs with the largest estimated holdings in IBRX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IBRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.